Corticosteroid administration does not affect viral oncolytic activity, but inhibits antitumor immunity in replication-competent herpes simplex virus tumor therapy

Human Gene Therapy

Volumn 10, Issue 17, 1999, Pages 2869-2878

  Todo, Tomoki ^a   Rabkin, Samuel D ^a   Chahlavi, Ali ^a   Martuza, Robert L ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CORTICOSTEROID; DEXAMETHASONE; G 207; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BRAIN TUMOR; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; DRUG EFFICACY; FEMALE; HERPES SIMPLEX VIRUS 1; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; TUMOR IMMUNITY; VIRUS CARCINOGENESIS; VIRUS REPLICATION;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; BIOLOGICAL THERAPY; COMBINED MODALITY THERAPY; CYTOPATHOGENIC EFFECT, VIRAL; DEXAMETHASONE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; NEOPLASM TRANSPLANTATION; NEUROBLASTOMA; SIMPLEXVIRUS; T-LYMPHOCYTES, CYTOTOXIC; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

ANIMALIA; HERPES; HUMAN HERPESVIRUS 1; MURINAE; SIMPLEXVIRUS;

EID: 0033589814     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/10430349950016591     Document Type: Article

References (47)

1. AMANO, T., RICHELSON, E., and NIRENBERG, M. (1972). Neurotransmitter synthesis by neuroblastoma clones. Proc. Natl. Acad. Sci. U.S.A. 69, 258-263.
2. BISCHOFF, J.R., KIRN, D.H., WILLIAMS, A., HEISE, C., HORN, S., MUNA, M., NG, L., NYE, J.A., SAMPSON-JOHANNES, A., FATTAEY, A., and McCORMICK, F. (1996). An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science 274, 373-376.
3. BOUVET, M., FANG, B., EKMEKCIOGLU, S., JI, L., BUCANA, C.D., HAMADA, K., GRIMM, E.A., and ROTH, J.A. (1998). Suppression of the immune response to an adenovirus vector and enhancement of intratumoral transgene expression by low-dose etoposide. Gene Ther. 5, 189-195.
4. BRAMSON, J.L., HITT, M., GAULDIE, J., and GRAHAM, F.L. (1997). Preexisting immunity to adenovirus does not prevent tumor regression following intratumoral administration of a vector expressing IL-12 but inhibits virus dissemination. Gene Ther. 4, 1069-1076.
5. CHAHLAVI, A., RABKIN, S.D., TODO, T., SUNDARESAN, P., and MARTUZA, R.L. (1999). Effect of prior exposure to herpes simplex virus 1 on viral vector mediated tumor therapy in immunocompetent mice. Gene Ther. 6, 1751-1758.
6. CHAMBERS, R., GILLESPIE, G.Y., SOROCEANU, L., ANDREANSKY, S., CHATTERJEE, S., CHOU, J., ROIZMAN, B., and WHITLEY, R.J. (1995). Comparison of genetically engineered herpes simplex viruses for the treatment of brain tumors in a scid mouse model of human malignant glioma. Proc. Natl. Acad. Sci. U.S.A. 92, 1411-1415.
7. CHOU, J., KERN, E.R., WHITLEY, R.J., and ROIZMAN, B. (1990). Mapping of herpes simplex virus-1 neurovirulence to gamma 34.5, a gene nonessential for growth in culture. Science 250, 1262-1266.
8. COFFEY, M.C., STRONG, J.E., FORSYTH, P.A., and LEE, P.W.K. (1998). Reovirus therapy of tumors with activated Ras pathway. Science 282, 1332-1334.
9. DENNIS, G.J., and MOND, J.J. (1986). Corticosteroid-induced suppression of murine B cell immune response antigens. J. Immunol. 136, 1600-1604.
10. DUBIN. G., SOCOLOF, E., FRANK, I., and FRIEDMAN, H.M. (1991). Herpes simplex virus type 1 Fc receptor protects infected cells from antibody-dependent cellular cytotoxicity. J. Virol. 65, 7046-7050.
11. ELSHAMI, A.A., KUCHARCZUK, J.C., STERMAN, D.H., SMYTHE, W.R., HWANG, H.C., AMIN, K.M., LITZKY, L.A., ALBELDA, S.M., and KAISER, L.R. (1995). The role of immunosuppression in the efficacy of cancer gene therapy using adenovirus transfer of the herpes simplex thymidine kinase gene. Ann. Surg. 222, 298-310.
12. FREIREICH, E.J., GEHAN, E.A., RALL, D.P., SCHMIDT, L.H., and SKIPPER, H.E. (1966). Quantitative comparison of oxicity of anticancer agents in mouse, rat, hamster, dog, moneky, and man. Cancer Chemother. Rep. 50, 219-244.
13. GOLDSTEIN, D.J., and WELLER, S.K. (1988). Herpes simplex virus type 1-induced ribonucleotide reductase activity is dispensable for virus growth and DNA synthesis: Isolation and characterization of an ICP6 lacZ insertion mutant. J. Virol. 62, 196-205.
14. HARE, L.E., YEH, K.C., DITZLER, C.A., McMAHON, F.G., and DUGGAN, D.E. (1975). Bioavailability of dexamethasone. II. Dexamethasone phosphate. J. Clin. Pharmacol. Ther. 18, 330-337.
15. HERRLINGER, U., KRAMM, C.M., ABOODY-GUTERMAN, K.S., SILVER, J.S., IKEDA, K., JOHNSTON, K.M., PECHAN, P.A., BARTH, R.F., FINKELSTEIN, D., CHIOCCA, E.A., LOUIS, D.N., and BREAKEFIELD, X.O. (1998). Pre-existing herpes simplex virus 1 (HSV-1) immunity decreases, but does not abolish, gene transfer to experimental brain tumors by a HSV-1 vector. Gene Ther. 5, 809-819.
16. HUNTER, W., RABKIN, S., and MARTUZA, R. (1995). Brain tumor therapy using genetically engineered replication-competent virus. In Viral Vectors. M.G. Kaplitt and A.D. Loewy, eds. (Academic Press, San Diego, CA) pp. 259-274.
17. JACOBSON, J.G., LEIB, D.A., GOLDSTEIN, D.J., BOGARD, C.L., SCHAFFER, P.A., WELLER, S.K., and COEN, D.M. (1989). A herpes simplex virus ribonucleotide reductase deletion mutant is defective for productive acute and reactivatable latent infections of mice and for replication in mouse cells. Virology 173, 276-283.
18. JAMES, C.B., VANDERPOOL, E.A., and ROANE, P. (1992). Acceleration of adenovirus replication and increased virion production by treatment with the steroid hormone 17 beta-estradiol. Microbiol. Immunol. 36, 99-103.
19. KEIL, D.E., LUEBKE, R.W., and PRUETT, S.B. (1995). Differences in the effects of dexamethasone on macrophage nitrite production: Dependence on exposure regimen (in vivo or in vitro) and activation stimuli. Int. J. Immunopharmacol. 17, 157-166.
20. KESARI, S., RANDAZZO, B.P., VALYI-NAGY, T., HUANG, Q.S., BROWN, S.M., MACLEAN, A.R., LEE, V.M., TROJANOWSKI, J.Q., and FRASER, N.W. (1995). Therapy of experimental human brain tumors using a neuroattenuated herpes simplex virus mutant. Lab. Invest. 73, 636-648.
21. KOEHLER, P.J. (1995). Use of corticosteroids in neuro-oncology. Anticancer Drugs 6, 19-33.
22. KUNICKA, J.E., TALLE, M.A., DENHARDT, G.H., BROWN, M., PRINCE, L.A., and GOLDSTEIN, G. (1993). Immunosuppression by glucocorticoids: Inhibition of production of multiple lymphokines by in vivo administration of dexamethasone. Cell Immunol. 149, 39-49.
23. LOPEZ, C. (1975). Genetics of natural resistance to herpesvirus infections in mice. Nature (London) 258, 152-155.
24. MARTUZA, R.L., MALICK, A., MARKERT, J.M., RUFFNER, K.L., and COEN, D.M. (1991). Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 252, 854-856.
25. MINETA, T., RABKIN, S.D., YAZAKI, T., HUNTER, W.D., and MARTUZA, R.L. (1995). Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature Med. 1, 938-943.
26. MIYATAKE, S., IYER, A., MARTUZA, R.L., and RABKIN, S.D. (1997). Transcriptional targeting of herpes simplex virus for cell-specific replication. J. Virol. 71, 5124-5132.
27. NADAI, T., SEIDA, M., NAKANISHI, K., YAMASHITA, S., SHIRAI, M., and OGAWA, Y. (1984). Comparison of the disposition after administration of dexamethasone phosphate solution and dexamethasone acetate suspension by different routes. Yakuri To Chiryo 12, 2877-2881.
28. NAKAMURA, T. (1981). Metabolism and effect on pituitary-adrenal cortex of injectable dexamethasone: Difference between steroid esters. Rinsho Yakuri 12, 1-16.
29. PYLES, R.B., WARNICK, R.E., CHALK, C.L., SZANTI, B.E., and PARYSEK, L.M. (1997). A novel multiply-mutated HSV-1 strain for the treatment of human brain tumors. Hum. Gene Ther. 8, 533-544.
30. RAGER-ZISMAN, B., and ALLISON, A.C. (1976). Mechanism of immunologic resistance to herpes simplex virus 1 (HSV-1) infection. J. Immunol. 116, 35-40.
31. RAM, Z., CULVER, K.W., WALBRIDGE, S., FRANK, J.A., BLAESE, R.M., and OLDFIELD, E.H. (1993). Toxicity studies of retroviral-mediated gene transfer for the treatment of brain tumors. J. Neurosurg. 79, 400-407.
32. RANDAZZO, B.P., KESARI, S., GESSER, R.M., ALSOP, D., FORD, J.C., BROWN, S.M., MACLEAN, A., and FRASER, N.W. (1995). Treatment of experimental intracranial murine melanoma with a neuroattenuated herpes simplex virus 1 mutant. Virology 211, 94-101.
33. RECOMBINANT DNA ADVISORY COMMITTEE (1998). Regulatory issues: Summary of protocol discussed at the June 18-19, 1998 Recombinant DNA Advisory Committee (RAC) meeting: ORDA gene transfer protocol registration: 9802-235 (a dose escalating phase I study of the treatment of malignant glioma with G207, a genetically engineered HSV-1). Hum. Gene Ther. 9, 2154-2155.
34. RODRIGUEZ, R., SCHUUR, E.R., LIM, H.Y., HENDERSON, G.A., SIMONS, J.W., and HENDERSON, D.R. (1997). Prostate attenuated replication competent adenovirus (ARCA) CN706: A selective cytotoxic for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57, 2559-2563.
35. SHAPIRO, W.R., and POSNER, J.B. (1974). Corticosteroid hormones: Effects in an experimental brain tumor. Arch. Neurol. 30, 217-221.
36. TODA, M., MARTUZA, R.L., and RABKIN, S.D. (1998a). In situ cancer vaccination: An IL-12 defective vector/replication-competent herpes simplex virus combination induces local and systemic antitumor activity. J. Immunol. 160, 4457-4464.
37. TODA, M., RABKIN, S.D., and MARTUZA, R.L. (1998b). Treatment of human breast cancer in a brain metastatic model by G207, a replication-competent multimutated herpes simplex virus 1. Hum. Gene Ther. 9, 2177-2185.
38. TODA, M., RABKIN, S.D., KOJIMA, H., and MARTUZA, R.L. (1999). Herpes simplex virus as an "in situ vaccine" for the induction of specific antitumor immunity. Hum. Gene Ther. 10, 385-393.
39. TODO, T., ADAMS, E.F., and FAHLBUSCH, R. (1993). Inhibitory effect of trapidil on human meningioma cell proliferation via interruption of autocrine growth stimulation. J. Neurosurg. 78, 463-469.
40. TODO, T., RABKIN, S.D., SUNDARESAN, P., WU, A., MEEHAN, K.R., HERSCOWITZ, H.B., and MARTUZA, R.L. (1999). Systemic antitumor immunity in experimental brain tumor therapy using a multimutated, replication-competent herpes simplex virus. Hum. Gene Ther. 10, 2741-2755.
41. TSURUFUJI, S., SUGIO, K., and TAKEMASA, F. (1979). The role of glucocorticoid receptor and gene expression in the anti-inflammatory action of dexamethasone. Nature (London) 280, 408-410.
42. WATANABE, S., NOHNO, T., OMUKAI, Y., SAITO, T., and SENOO, T. (1982). Stimulatory effects of dexamethasone and indomethacin on growth of androgen-dependent Shionogi carcinoma 115 in the mouse. Cancer Lett. 16, 261-266.
43. WHITLEY, R.J. (1996). Herpes simplex viruses. In Fields Virology, 3rd Ed., B.N. Fields, D.M. Knipe, and P.M. Howley, eds. (Lippincott-Raven, Philadelphia) pp. 2297-2342.
44. YANG, Y., NUNES, F.A., BERENCSI, K., FURTH, E.E., GÖNCZÖL, E., and WILSON, J.M. (1994). Cellular immunity to viral antigens limits E1-deleted adenoviruses for gene transfer. Proc. Natl. Acad. Sci. U.S.A. 91, 4407-4411.
45. YANG, Y., LI, Q., ERTL, H.C.J., and WILSON, J.M. (1995). Cellular and humoral immune responses to viral antigens create barriers to lung-directed gene therpay with recombinant adenoviruses. J. Virol. 69, 2004-2015.
46. YANG, Y., GREENOUGH, K., and WILSON, J.M. (1996). Transient immune blockage prevents formation of neutralizing antibody to recombinant adenovirus and allows repeated gene transfer to mouse liver. Gene Ther. 3, 412-420.
47. YAZAKI, T., MANZ, H.J., RABKIN, S.D., and MARTUZA, R.L. (1995). Treatment of human malignant meningiomas by G207, a replication-competent multimutated herpes simplex virus 1. Cancer Res. 55, 4752-4756.